Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients

Michael A. Levesque, Dionyssios Katsaros, He Yu, Maurizia Giai, Franco Genta, Riccardo Roagna, Riccardo Ponzone, Marco Massobrio, Piero Sismondi, Eleftherios P. Diamandis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The prognostic value of p53 protein accumulation in breast cancer, especially as detected by methods other than immunohistochemistry, has not been established unequivocally. A sensitive immunofluorometric assay of p53 protein employing DO-1 and CM-1 antibodies was used in this study to assay extracts of 171 breast carcinomas from northern Italy. p53 over-expression, demonstrated in 36 (21%) tumours, was associated with lack of oestrogen receptor (ER) expression but was not related to patient age, stage, lymph node status, tumour size, histologic type, grade or progesterone receptor (PR) expression status in contingency tables. An increased risk for cancer relapse of p53-positive patients compared to p53-negative patients was determined using multivariate Cox regression analysis, which also showed that p53 protein over-expression was an independent predictor of reduced disease- free survival in node-positive and ER+ patients but not in node-negative or ER- individuals. The equivalent analysis for assessing the impact of p53 status on overall survival was not statistically significant, possibly reflecting the short patient follow-up. Our results suggest that an immunoassay of p53 protein, applicable to cytosolic extracts prepared for steroid hormone receptor analyses, may provide information for breast cancer prognosis.

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalInternational Journal of Cancer
Volume79
Issue number2
DOIs
Publication statusPublished - 1998

Fingerprint

Breast Neoplasms
Proteins
Fluoroimmunoassay
Neoplasms
Steroid Receptors
Progesterone Receptors
Immunoassay
Estrogen Receptors
Italy
Disease-Free Survival
Lymph Nodes
Immunohistochemistry
Regression Analysis
Hormones
Recurrence
Survival
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. / Levesque, Michael A.; Katsaros, Dionyssios; Yu, He; Giai, Maurizia; Genta, Franco; Roagna, Riccardo; Ponzone, Riccardo; Massobrio, Marco; Sismondi, Piero; Diamandis, Eleftherios P.

In: International Journal of Cancer, Vol. 79, No. 2, 1998, p. 147-152.

Research output: Contribution to journalArticle

Levesque, Michael A. ; Katsaros, Dionyssios ; Yu, He ; Giai, Maurizia ; Genta, Franco ; Roagna, Riccardo ; Ponzone, Riccardo ; Massobrio, Marco ; Sismondi, Piero ; Diamandis, Eleftherios P. / Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. In: International Journal of Cancer. 1998 ; Vol. 79, No. 2. pp. 147-152.
@article{7814add487524803b5696b575f9d8354,
title = "Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients",
abstract = "The prognostic value of p53 protein accumulation in breast cancer, especially as detected by methods other than immunohistochemistry, has not been established unequivocally. A sensitive immunofluorometric assay of p53 protein employing DO-1 and CM-1 antibodies was used in this study to assay extracts of 171 breast carcinomas from northern Italy. p53 over-expression, demonstrated in 36 (21{\%}) tumours, was associated with lack of oestrogen receptor (ER) expression but was not related to patient age, stage, lymph node status, tumour size, histologic type, grade or progesterone receptor (PR) expression status in contingency tables. An increased risk for cancer relapse of p53-positive patients compared to p53-negative patients was determined using multivariate Cox regression analysis, which also showed that p53 protein over-expression was an independent predictor of reduced disease- free survival in node-positive and ER+ patients but not in node-negative or ER- individuals. The equivalent analysis for assessing the impact of p53 status on overall survival was not statistically significant, possibly reflecting the short patient follow-up. Our results suggest that an immunoassay of p53 protein, applicable to cytosolic extracts prepared for steroid hormone receptor analyses, may provide information for breast cancer prognosis.",
author = "Levesque, {Michael A.} and Dionyssios Katsaros and He Yu and Maurizia Giai and Franco Genta and Riccardo Roagna and Riccardo Ponzone and Marco Massobrio and Piero Sismondi and Diamandis, {Eleftherios P.}",
year = "1998",
doi = "10.1002/(SICI)1097-0215(19980417)79:2<147::AID-IJC9>3.0.CO;2-T",
language = "English",
volume = "79",
pages = "147--152",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients

AU - Levesque, Michael A.

AU - Katsaros, Dionyssios

AU - Yu, He

AU - Giai, Maurizia

AU - Genta, Franco

AU - Roagna, Riccardo

AU - Ponzone, Riccardo

AU - Massobrio, Marco

AU - Sismondi, Piero

AU - Diamandis, Eleftherios P.

PY - 1998

Y1 - 1998

N2 - The prognostic value of p53 protein accumulation in breast cancer, especially as detected by methods other than immunohistochemistry, has not been established unequivocally. A sensitive immunofluorometric assay of p53 protein employing DO-1 and CM-1 antibodies was used in this study to assay extracts of 171 breast carcinomas from northern Italy. p53 over-expression, demonstrated in 36 (21%) tumours, was associated with lack of oestrogen receptor (ER) expression but was not related to patient age, stage, lymph node status, tumour size, histologic type, grade or progesterone receptor (PR) expression status in contingency tables. An increased risk for cancer relapse of p53-positive patients compared to p53-negative patients was determined using multivariate Cox regression analysis, which also showed that p53 protein over-expression was an independent predictor of reduced disease- free survival in node-positive and ER+ patients but not in node-negative or ER- individuals. The equivalent analysis for assessing the impact of p53 status on overall survival was not statistically significant, possibly reflecting the short patient follow-up. Our results suggest that an immunoassay of p53 protein, applicable to cytosolic extracts prepared for steroid hormone receptor analyses, may provide information for breast cancer prognosis.

AB - The prognostic value of p53 protein accumulation in breast cancer, especially as detected by methods other than immunohistochemistry, has not been established unequivocally. A sensitive immunofluorometric assay of p53 protein employing DO-1 and CM-1 antibodies was used in this study to assay extracts of 171 breast carcinomas from northern Italy. p53 over-expression, demonstrated in 36 (21%) tumours, was associated with lack of oestrogen receptor (ER) expression but was not related to patient age, stage, lymph node status, tumour size, histologic type, grade or progesterone receptor (PR) expression status in contingency tables. An increased risk for cancer relapse of p53-positive patients compared to p53-negative patients was determined using multivariate Cox regression analysis, which also showed that p53 protein over-expression was an independent predictor of reduced disease- free survival in node-positive and ER+ patients but not in node-negative or ER- individuals. The equivalent analysis for assessing the impact of p53 status on overall survival was not statistically significant, possibly reflecting the short patient follow-up. Our results suggest that an immunoassay of p53 protein, applicable to cytosolic extracts prepared for steroid hormone receptor analyses, may provide information for breast cancer prognosis.

UR - http://www.scopus.com/inward/record.url?scp=17144472315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144472315&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19980417)79:2<147::AID-IJC9>3.0.CO;2-T

DO - 10.1002/(SICI)1097-0215(19980417)79:2<147::AID-IJC9>3.0.CO;2-T

M3 - Article

C2 - 9583729

AN - SCOPUS:17144472315

VL - 79

SP - 147

EP - 152

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -